Plasma ADMA Predicts Restenosis of Arteriovenous Fistula
- 1 January 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 20 (1), 213-222
- https://doi.org/10.1681/asn.2008050476
Abstract
Plasma levels of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide production, correlate with endothelial dysfunction and the development of cardiovascular events in patients with uremia. It is not known whether endothelial dysfunction contributes to the dysfunction of arteriovenous fistulas (AVFs) in hemodialysis patients. Here, we studied the predictive value of baseline plasma ADMA for symptomatic restenosis of an AVF after percutaneous transluminal angioplasty in dialysis patients. We obtained baseline plasma ADMA levels before percutaneous transluminal angioplasty in 100 consecutive patients with dysfunctional AVFs. Patients were followed up clinically for up to 6 mo after angioplasty for recurrent dysfunction. During the 6 mo after angioplasty, 46 patients experienced recurrent dysfunction of their AVF; of these, follow-up fistulography showed restenosis at the same location in 41, new stenosis at different locations in two, and no significant stenosis in three patients. Up to 60% of the patients with high levels of ADMA (>0.910 μM) had target lesion restenosis compared with 25% of those with low levels (P < 0.001). In multivariate analysis, plasma ADMA independently nearly tripled the risk for recurrent symptomatic stenosis of an AVF after percutaneous transluminal angioplasty (hazard ratio 2.65; 95% confidence interval 1.33 to 5.28). These results suggest a role for ADMA in the progression of symptomatic restenoses of AVFs after percutaneous transluminal angioplasty and call for preventive strategies that target ADMA and/or endothelial dysfunction to decrease the risk for AVF restenosis.Keywords
This publication has 48 references indexed in Scilit:
- Asymmetrical Dimethylarginine in Renal Disease: Limits of Variation or Variation Limits?American Journal of Nephrology, 2007
- Prevalence of Dementia Subtypes in El Prat de Llobregat, Catalonia, Spain: The PRATICON StudyNeuroepidemiology, 2007
- Association of Homocysteine and Asymmetric Dimethylarginine With Atherosclerosis and Cardiovascular Events in Maintenance Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2006
- Length polymorphism in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patientsKidney International, 2006
- Inflammation and restenosis after percutaneous coronary interventionsEuropean Heart Journal, 2004
- Transforming growth factor β1 genotype polymorphisms determine AV fistula patency in hemodialysis patientsKidney International, 2003
- Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine DimethylaminohydrolaseArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosisKidney International, 2002
- Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan‐induced hyperglycaemiaBritish Journal of Pharmacology, 1999
- Percutaneous transvenous angioplasty in the treatment of vascular access stenosisKidney International, 1992